Geneva Capital Management LLC Trims Stake in Intuitive Surgical, Inc. (NASDAQ:ISRG)

Geneva Capital Management LLC cut its position in shares of Intuitive Surgical, Inc. (NASDAQ:ISRG) by 8.0% during the 3rd quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 3,963 shares of the medical equipment provider’s stock after selling 345 shares during the quarter. Geneva Capital Management LLC’s holdings in Intuitive Surgical were worth $1,947,000 as of its most recent filing with the Securities & Exchange Commission.

Several other hedge funds and other institutional investors also recently added to or reduced their stakes in ISRG. Vanguard Group Inc. boosted its holdings in shares of Intuitive Surgical by 1.6% during the 1st quarter. Vanguard Group Inc. now owns 30,868,620 shares of the medical equipment provider’s stock valued at $12,319,358,000 after buying an additional 493,126 shares in the last quarter. Capital World Investors boosted its stake in Intuitive Surgical by 1.0% during the first quarter. Capital World Investors now owns 7,284,269 shares of the medical equipment provider’s stock worth $2,907,079,000 after acquiring an additional 73,634 shares in the last quarter. Baillie Gifford & Co. grew its holdings in Intuitive Surgical by 0.6% in the third quarter. Baillie Gifford & Co. now owns 3,848,547 shares of the medical equipment provider’s stock worth $1,890,676,000 after purchasing an additional 24,183 shares during the period. American Century Companies Inc. grew its holdings in Intuitive Surgical by 3.0% in the second quarter. American Century Companies Inc. now owns 2,398,193 shares of the medical equipment provider’s stock worth $1,066,837,000 after purchasing an additional 70,556 shares during the period. Finally, Clearbridge Investments LLC lifted its holdings in shares of Intuitive Surgical by 1.6% during the second quarter. Clearbridge Investments LLC now owns 1,981,297 shares of the medical equipment provider’s stock valued at $881,380,000 after purchasing an additional 30,449 shares during the last quarter. 83.64% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

A number of research analysts recently weighed in on ISRG shares. Redburn Atlantic raised Intuitive Surgical from a “neutral” rating to a “buy” rating and raised their price objective for the company from $380.00 to $510.00 in a research report on Friday, August 2nd. Leerink Partners lifted their price target on Intuitive Surgical from $489.00 to $502.00 in a research report on Thursday, October 17th. Royal Bank of Canada increased their price objective on shares of Intuitive Surgical from $525.00 to $555.00 and gave the company an “outperform” rating in a research report on Friday, October 18th. Piper Sandler restated an “overweight” rating and set a $538.00 price objective (up from $495.00) on shares of Intuitive Surgical in a research note on Friday, October 18th. Finally, Evercore ISI reiterated a “cautious” rating on shares of Intuitive Surgical in a research note on Friday, October 18th. One research analyst has rated the stock with a sell rating, five have assigned a hold rating and fourteen have given a buy rating to the company. Based on data from MarketBeat.com, Intuitive Surgical has an average rating of “Moderate Buy” and an average price target of $513.74.

Intuitive Surgical Trading Up 0.2 %

ISRG opened at $537.07 on Wednesday. The company’s 50 day moving average is $494.78 and its 200 day moving average is $453.94. The company has a market cap of $191.29 billion, a price-to-earnings ratio of 86.35, a PEG ratio of 5.27 and a beta of 1.39. Intuitive Surgical, Inc. has a 12-month low of $281.12 and a 12-month high of $542.59.

Intuitive Surgical (NASDAQ:ISRG) last issued its quarterly earnings results on Thursday, October 17th. The medical equipment provider reported $1.56 earnings per share for the quarter, topping the consensus estimate of $1.24 by $0.32. The business had revenue of $2.04 billion for the quarter, compared to analysts’ expectations of $2.01 billion. Intuitive Surgical had a net margin of 28.51% and a return on equity of 13.41%. As a group, analysts predict that Intuitive Surgical, Inc. will post 5.45 EPS for the current fiscal year.

Insider Buying and Selling

In other news, insider Jamie Samath sold 22,903 shares of the stock in a transaction on Friday, November 8th. The shares were sold at an average price of $525.00, for a total value of $12,024,075.00. Following the completion of the sale, the insider now directly owns 8,757 shares of the company’s stock, valued at $4,597,425. This represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. In related news, insider Jamie Samath sold 22,903 shares of Intuitive Surgical stock in a transaction that occurred on Friday, November 8th. The stock was sold at an average price of $525.00, for a total transaction of $12,024,075.00. Following the sale, the insider now owns 8,757 shares of the company’s stock, valued at approximately $4,597,425. This trade represents a 0.00 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, SVP Henry L. Charlton sold 40,243 shares of the company’s stock in a transaction that occurred on Friday, August 23rd. The stock was sold at an average price of $486.84, for a total value of $19,591,902.12. Following the completion of the transaction, the senior vice president now owns 3,001 shares of the company’s stock, valued at $1,461,006.84. The trade was a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last ninety days, insiders sold 91,178 shares of company stock valued at $45,897,071. 0.80% of the stock is owned by corporate insiders.

Intuitive Surgical Company Profile

Intuitive Surgical, Inc develops, manufactures, and markets products that enable physicians and healthcare providers to enhance the quality of and access to minimally invasive care in the United States and internationally. The company offers the da Vinci Surgical System that enables complex surgery using a minimally invasive approach; and Ion endoluminal system, which extends its commercial offerings beyond surgery into diagnostic procedures enabling minimally invasive biopsies in the lung.